


ADLER AND ASSOCIATES 7132705361 PAGE 02 THUMBE H NTS TO THE CLAIMS release of Claim 1 (withda emitting radioactive decay intermediate radionuclide to an individual, con incorporating sa having a diameter sufficient intermediates; and administering said large within said large liposomes of said radionuclide reduces the systemic re Claim 2 (withdrawn): prior to entrapping said incorporating said radionuclide liposome. Claim 3 (withdrawith) labeling said sma Claim 4 (withdrawn): The method of: . coating outer mark which preferentially associate with a speci said large liposomes to said target cell Claim 5 (withdrawn): The metho cancer cell, a virally infected cell, an autoimm Claim 6 (withdrawn): The method antibodies, peptides, engineered (noticula Claim 7 (withdrawn): said antibodies are Herceptin.








ADLER AND ASSOCIATES said alpha ethod of c Claim 32 (origina adjonuclide, particle-emitting radionuclide is **i**posomal wherein said beta particle emitting vesides. Claim 33 (original) particle-emitting radionuclide is *** processing Claim 34 (withdraw reduced HER-2/neu protein in an individui systemic release of radioactive d entrapping said Ag of large incorporating said brity of the liposomes, said liposomes havin radioactive decay intermediates outer polyethyleneglycql-linked membranes thereof; and Herceptin antiboo delivering said Ap-2 the HER-2/neu protein expressed on the of said radioactive decay into systemic release thereof. Claim 35 (withdrawn): The me labeling said smaller liposoma Claim 36 (withdrawn): The math steps of: preinjecting the individual saturating the reliculoendothelial spleen and liver uptake of said

in in the second second



PAGE 8/10 * RCVD AT 2/9/2009 5:07:14 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/25 * DNIS:2738300 * CSID:7132705361 * DURATION (mm-ss):16-20

